Navigation Links
Beardsworth Continues to Strengthen Oncology Operations
Date:5/4/2011

FLEMINGTON, N.J., May 4, 2011 /PRNewswire/ -- Beardsworth announces the promotion of Evette Riegel, RN, to Senior Director, Clinical Operations and Project Management and the addition of Saishree Ramalingam, MS, MPhil as Senior Project Manager.  

(Photo:  http://photos.prnewswire.com/prnh/20110504/NY95605 )

In her new role, Ms. Riegel will lead Beardsworth's expanded focus in oncology clinical operations and execution of all clinical programs.

"Evette's expertise and insight provide an added dimension that strengthens our client services and capabilities across our global OncologyOne(SM) and therapeutic vaccine initiatives.  Her global trial experience and extensive therapeutic knowledge combined with her personal insight as a critical care nurse, give her a unique perspective from which to lead our patient-centric, project management teams," said Michael O'Brien, President & CEO.

Ms. Riegel joined Beardsworth in 2006 as a Senior Project Manager and became Director, Clinical Operations in 2008 with a leading role in the integration of Beardsworth's global services and oncology operations. Previously, Ms. Riegel worked at Quintiles as a global project manager as well as Discovery Laboratories, ViroPharma, and Wyeth.

Saishree Ramalingam, MS, MPhil joins Beardsworth as a Senior Project Manager responsible for leading the company's oncology trials. An experienced research clinician, Ms. Ramalingam has over 13 years experience across multiple therapeutic areas and global projects with a special focus in oncology and vaccines.

Prior to Beardsworth, Ms. Ramalingam held project manager positions at Celgene, Pfizer, GSK/Reliant, Merck, as well as PharmaNet, Applied Clinical Intelligence, and PRA International. She received her master of science at the University of Akron and a master of philosophy from Avinashilingam Deemed University, Coimbatore, India.

"We are thrilled to have Saishree on the Beardsworth team," said Evette Riegel. "The depth and scope of her expertise, global project experience, and strong cross-functional leadership capabilities are immediate assets to our clients, our partners, and our project teams."

Headquartered in Flemington, New Jersey, Beardsworth is a full-service CRO specializing in business solutions for complex clinical trials focused on oncology and therapeutic vaccine. Our multi-disciplined staff averages 20+ years experience supporting research studies from trial design through clinical project management to FDA approval. Beardsworth is the founding partner of OncologyOne(SM) – an alliance of best-in-class regional CROs providing full-service strategies for global oncology trials. Celebrating its 25th year, Beardsworth is a CCR registrant and Certified Small Business.

www.beardsworth.com


'/>"/>
SOURCE Beardsworth
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Alison Martin, MD and Robert W. Malone, MD Join Beardsworth
2. InstaCare Corp. Continues Turnaround & Reports 291% Revenues Increase in 2Q 2008
3. China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base
4. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
5. Use of Biologic Agents Continues to Expand Among US Rheumatologists - Can New Agents Shift the Treatment Paradigm in Rheumatoid Arthritis?
6. Investment and Growth in US Medical Technology Industry Continues Despite Challenging Public Markets
7. FDA Continues Review of Takedas New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes
8. Custom NX(R) Drug Eluting Stent System Continues to Demonstrate Favorable Outcomes in Challenging Patient Populations at One, Two and Three Years
9. ATS Forcefield Anti-platelet Technology Continues to Demonstrate Positive Results
10. ACORN CRO Continues Growth in Strong Third Quarter
11. Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/14/2017)... ... September 14, 2017 , ... AIM Global, the worldwide standards ... Inc. has won the 2017 Case Study Competition for AIDC. The award is ... that decrease risk” and push the adoption of automated data collection systems further. ...
(Date:9/12/2017)... ... September 12, 2017 , ... ... scalable cloud-based platform for ambulatory patient monitoring and clinical trial support, earned DPharm ... Trials conference in Boston. , Launched in 2005, PhysIQ leverages artificial intelligence ...
(Date:9/12/2017)... ... September 12, 2017 , ... Soybean researchers ... to submit a "pre-proposal” by October 15, prior to completing a full grant ... are aligned with our priorities, and to encourage researchers to further develop ones ...
(Date:9/12/2017)... & Cambridge (PRWEB) , ... September 11, 2017 ... ... with US offices in Cambridge, MA, announce today that Holotype HLA and other ... at the annual meeting of the American Society for Histocompatibility and Immunogenetics ...
Breaking Biology Technology:
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:3/30/2017)... March 30, 2017 Trends, opportunities and forecast ... behavioral), by technology (fingerprint, AFIS, iris recognition, facial recognition, ... others), by end use industry (government and law enforcement, ... and banking, and others), and by region ( ... Asia Pacific , and the Rest ...
(Date:3/24/2017)... Research and Markets has announced the addition ... Trends - Industry Forecast to 2025" report to their offering. ... The Global Biometric ... of around 15.1% over the next decade to reach approximately $1,580 ... market estimates and forecasts for all the given segments on global ...
Breaking Biology News(10 mins):